Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑({6‑[(4‑cyano‑2‑fluorobenzyl)oxy]naphthalen‑2‑yl}sulfonyl)‑D‑glutamic acid is a synthetic small molecule designed as an inhibitor of the bacterial enzyme UDP-N-acetylmuramoyl-L-alanine–D-glutamate ligase, commonly known as MurD. This enzyme is essential in the biosynthesis of peptidoglycan, a critical component of bacterial cell walls. By inhibiting MurD, this compound disrupts cell wall formation and has potential antibacterial activity. It is primarily studied in preclinical or early experimental settings and has not been approved for clinical use[1][6]. The compound belongs to the class of glutamic acid derivatives.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-({6-[(4-cyano-2-fluorobenzyl)oxy]naphthalen-2-yl}sulfonyl)-D-glutamic acid.